UK markets closed

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
173.25-3.10 (-1.76%)
At close: 04:00PM EST
173.32 +0.07 (+0.04%)
After hours: 07:57PM EST
Full screen
Trade prices are not sourced from all markets
Previous close176.35
Open172.74
Bid173.05 x 1100
Ask173.64 x 1400
Day's range172.40 - 178.74
52-week range115.03 - 217.25
Volume2,464,103
Avg. volume5,022,640
Market cap66.559B
Beta (5Y monthly)1.71
PE ratio (TTM)6.48
EPS (TTM)26.74
Earnings date23 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est226.64
  • Motley Fool

    3 No-Brainer Growth Stocks to Buy in 2023

    In last-year's difficult market, growth stocks were among the first to suffer. Why should we be confident about growth stocks? Moderna (NASDAQ: MRNA) went from zero product revenue prior to the pandemic to about $18 billion annually over the past two years.

  • Business Wire

    Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials

    FREMONT, Calif., February 03, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, kn

  • Motley Fool

    Is Moderna Stock a Buy Now?

    The past three years have been fascinating for Moderna (NASDAQ: MRNA) and its shareholders. Moderna's shares are up by an impressive 731% since early 2020, although its coronavirus-related sales will start falling this year. At this point, it's fair to ask if Moderna can march on and continue delivering market-beating returns, or if the company won't be worth an investment in a post-pandemic world.